-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Although no adverse events such as myocarditis and pericarditis were observed in the 2019 coronavirus disease ( COVID-19 ) vaccine trial, there have been a large number of reports of suspected myocarditis and pericarditis cases after vaccination in the general population
COVID-19
Recently, a research article was published in the top medical journal Nature Medicine.
Arrhythmia
The researchers found that 1-28 days after vaccination and after testing positive for SARS-CoV-2, the risk of myocarditis associated with the first dose of ChAdOx1 and BNT162b2 vaccine and the first and second doses of mRNA-1273 vaccine increased
In contrast, within 28 days of testing positive for SARS-CoV-2, an additional 40 (95% CI 38-41) myocarditis events occurred per million patients
It can be seen that, except for the increased risk of arrhythmia after the second dose of mRNA-1273 vaccine, no similar association has been observed in any COVID-19 vaccine
Except for the increased risk of arrhythmia after the second dose of mRNA-1273 vaccine, no similar association has been observed in any COVID-19 vaccine
Original source:
Martina Patone,et al.
Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection
in this message